FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.